Cogent Biosciences, Inc.

COGT

US19240Q2012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
7.44 ^USD	-0.40%		-1.59%	+26.53%

07/05	Cogent Biosciences Q1 Loss Widens	MT
07/05	Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Unum Therapeutics Inc. will Change its Name to Cogent Biosciences, Inc

October 06, 2020 at 09:30 am IST

Effective October 06, 2020, Unum Therapeutics Inc. will change its name to Cogent Biosciences, Inc.

Latest news about Cogent Biosciences, Inc.

Cogent Biosciences Q1 Loss Widens	07/05	MT
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
North American Morning Briefing : Stock Futures -2-	27/02	DJ
Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	26/02	MT
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02	CI
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02	CI
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	26/02	MT
Transcript : Cogent Biosciences, Inc. - Special Call	23/02
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	23/02	MT
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	23/02	CI
Top Midday Gainers	15/02	MT
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump	14/02	MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	08/02	MT
Transcript : Cogent Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	10/01
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024	10/01	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	15/12	MT
North American Morning Briefing : Traders Eye -2-	12/12	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	12/12	MT
Top Midday Decliners	12/12	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	12/12	MT
Cogent Biosciences Says Phase 2 Trial of Bezuclastinib Showed 4 Related Serious Adverse Events; Shares Down	11/12	MT
Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis	11/12	CI
Transcript : Cogent Biosciences, Inc. - Special Call	11/12
Cogent Biosciences Announces Positive Data from Part 1 of the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis	11/12	CI
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	11/12	MT

Chart Cogent Biosciences, Inc.

Duration

Period

More charts

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Companyâs clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3KÎ±. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Sector

Biotechnology & Medical Research

Calendar

02/06/2024 - American Society of Clinical Oncology Annual Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.44 USD

Average target price

17.18 USD

Spread / Average Target

+130.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COGENT BIOSCIENCES, INC.	+26.53%	711M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs

Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Biotechnology & Medical Research

Unum Therapeutics Inc. will Change its Name to Cogent Biosciences, Inc

Latest news about Cogent Biosciences, Inc.

Chart Cogent Biosciences, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs